Skip to main content

Advertisement

Table 3 Cardiovascular safety markers, part II

From: Safety of TeaCrine®, a non-habituating, naturally-occurring purine alkaloid over eight weeks of continuous use

Variable T1 T2 T3 Time*group Time*group*gender
RR Interval (ms)
 PLA 1011 ± 148 991 ± 147 976 ± 113 Time p = 0.23 G*T*Ge p = 0.68
 LD 1095 ± 240 1041 ± 185 1035 ± 212 G*T p = 0.55
 HD 987 ± 213 1043 ± 221 1007 ± 198
PR Interval (ms)
 PLA 155 ± 25 155 ± 18 156 ± 20 Time p = 0.49 G*T*Ge p = 0.42
 LD 153 ± 18 153 ± 20 154 ± 17 G*T p = 0.33
 HD 150 ± 24 144 ± 24 143 ± 19
QRS Duration (ms)
 PLA 95 ± 11 91 ± 22 96 ± 12 Time p = 0.32 G*T*Ge p = 0.25
 LD 93 ± 12 93 ± 11 94 ± 11 G*T p = 0.41
 HD 92 ± 13 92 ± 12 92 ± 12
QT Interval (ms)
 PLA 428 ± 27 424 ± 31 424 ± 25 Time p = 0.33 G*T*Ge p = 0.38
 LD 427 ± 40 424 ± 36 419 ± 38 G*T p = 0.36
 HD 409 ± 26 614 ± 904 418 ± 38
QTc Interval (ms)
 PLA 429 ± 17 426 ± 19 427 ± 22 Time p = 0.89 G*T*Ge p = 0.35
 LD 421 ± 24 422 ± 22 419 ± 23 G*T p = 0.33
 HD 414 ± 19 417 ± 20 419 ± 27
QT Dispersion (ms)
 PLA 38 ± 25 33 ± 18 36 ± 42 Time p = 0.78 G*T*Ge p = 0.11
 LD 35 ± 21 51 ± 90 38 ± 25 G*T p = 0.51
 HD 41 ± 27 32 ± 21 32 ± 27
P Axis (degrees)
 PLA 54 ± 31 65 ± 12 59 ± 25 Time p = 0.66 G*T*Ge p = 0.88
 LD 52 ± 37 53 ± 37 53 ± 35 G*T p= 0.033
 HD 61 ± 15 54 ± 19 59 ± 17
R Axis (degrees)
 PLA 73 ± 32 78 ± 26 76 ± 33 Time p = 0.81 G*T*Ge p = 0.13
 LD 74 ± 25 67 ± 33 72 ± 26 G*T p = 0.38
 HD 85 ± 9 84 ± 9 84 ± 11
T Axis (degrees)
 PLA 54 ± 20 415 ± 1587 59 ± 14 Time p = 0.15 G*T*Ge p = 0.34
 LD 61 ± 17 438 ± 1653 60 ± 17 G*T p = 0.90
 HD 200 ± 634 312 ± 1160 60 ± 17
  1. Abbreviations: PLA Placebo, LD Theacrine Low Dose, HD Theacrine High Dose, G Group, T Time, Ge Gender
  2. Items in bold indicate a significant effect (p < 0.05) was observed